SEC 13F Intelligence

Managers / Q2 2021 · view latest →

Altium Capital Management LLC

CIK 0001746382 · 152 W 57 ST FL7, NEW YORK, NY, 10019 · 2124842711

Reported Value
$431M
Q2 2021
Positions
135
Filings on Record
25
2019–present window
Filed
Aug 13, 2021
original filing

Summary

Altium Capital Management LLC reported $431M in U.S.-listed holdings across 135 positions for Q2 2021.

Its largest position, 1847 Goedeker, represents 3.4% of the portfolio.

Compared with Q1 2021, the fund opened 54 new positions and exited 43.

Portfolio Metrics

Turnover
+33.8%
vs prior filed quarter
Top-10 Concentration
+23.2%
share of reported value
Largest Position
+3.4%
1847 Goedeker
New / Exited
54 / 43
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’20: $266MQ4 ’20Q1 ’21: $360MQ2 ’21: $431MQ3 ’21: $381MQ3 ’21Q4 ’21: $363MQ1 ’22: $299MQ2 ’22: $250MQ2 ’22Q3 ’22: $273MQ4 ’22: $197MQ1 ’23: $180MQ1 ’23Q2 ’23: $132MQ3 ’23: $192MQ4 ’23: $147MQ4 ’23Q1 ’24: $253MQ2 ’24: $245MQ3 ’24: $340MQ3 ’24Q4 ’24: $353MQ1 ’25: $42MQ2 ’25: $0Q2 ’25Q3 ’25: $628,262Q4 ’25: $25MQ1 ’26: $42MQ1 ’26filingsflow.com

Portfolio Composition

By security type
Common Stock: 70.4%Other: 27.7%Equity WRT: 1.0%ADR: 0.9%
  • Common Stock · 70.4% · $304M
  • Other · 27.7% · $119M
  • Equity WRT · 1.0% · $4M
  • ADR · 0.9% · $4M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2021 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
1847 GOEDEKER INCNEW+6.89M6.89M+$15M$15M
XTNTXTANT MED HLDGS INCNEW+8.29M8.29M+$14M$14M
KALEYRA INCNEW+640.0K640.0K+$8M$8M
PALISADE BIO INCNEW+1.82M1.82M+$7M$7M
ELECTROCORE INCNEW+5.00M5.00M+$6M$6M
NOCTURNE ACQUISITION CORPNEW+500.0K500.0K+$5M$5M
CERSCERUS CORPNEW+814.3K814.3K+$5M$5M
BRIACELL THERAPEUTICS CORPNEW+800.3K800.3K+$4M$4M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2021

128 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
11847 GOEDEKER INC*W EXP 99/99/9993.42%$15M6.89M
2XTNTXTANT MED HLDGS INChistory →COM NEW3.14%$14M8.29M
3PTGXPROTAGONIST THERAPEUTICS INChistory →COM2.94%$13M282.4K
4CRNXCRINETICS PHARMACEUTICALS INhistory →COM2.33%$10M533.0K
5ALDXALDEYRA THERAPEUTICS INChistory →COM2.27%$10M864.0K
6CTI BIOPHARMA CORPCOM2.13%$9M3.68M
7CHARDAN HEALTHCR ACQSTN 2 COCOM · *W EXP 03/05/2021.85%$8M1.49M
8KALEYRA INCCOM1.82%$8M640.0K
9PALISADE BIO INCCOM1.72%$7M1.82M
10VERASTEM INCCOM1.62%$7M1.72M
11CURIS INCCOM NEW1.55%$7M829.0K
12LNTHLANTHEUS HLDGS INChistory →COM1.54%$7M240.1K
13ARQTARCUTIS BIOTHERAPEUTICS INChistory →COM1.46%$6M231.3K
14ESSA PHARMA INCCOM NEW1.41%$6M213.5K
15ELECTROCORE INCCOM1.38%$6M5.00M
16VERRICA PHARMACEUTICALS INCCOM1.38%$6M525.1K
17CHINOOK THERAPEUTICS INCCOM1.36%$6M416.6K
18SYROS PHARMACEUTICALS INCCOM1.36%$6M1.08M
19CDNACAREDX INChistory →COM1.35%$6M63.4K
20INSMINSMED INChistory →COM PAR $.011.34%$6M203.4K
21IVERIC BIO INCCOM1.32%$6M902.6K
22BLUBELLUS HEALTH INC NEWhistory →COM NEW1.29%$6M1.79M
23GMEDGLOBUS MED INChistory →CL A1.27%$5M70.8K
24CTMXCYTOMX THERAPEUTICS INChistory →COM1.27%$5M862.4K
25MYGNMYRIAD GENETICS INChistory →COM1.21%$5M171.2K
26MEI PHARMA INCCOM NEW1.21%$5M1.83M
27NOCTURNE ACQUISITION CORPORDINARY SHARES · RIGHT 12/26/20251.19%$5M1.00M
28CSTLCASTLE BIOSCIENCES INChistory →COM1.17%$5M69.0K
29SIENTRA INCCOM1.12%$5M605.7K
30CERSCERUS CORPhistory →COM1.12%$5M814.3K
31PODDINSULET CORPhistory →COM1.08%$5M17.0K
32AVIDITY BIOSCIENCES INCCOM1.08%$5M188.6K
33BRIACELL THERAPEUTICS CORPCOM NEW · *W EXP 02/24/2021.08%$5M1.01M
34NEVRO CORPCOM1.03%$4M26.9K
35IMMATICS N.VSHS · *W EXP 07/01/2021.01%$4M442.0K
36AUPHAURINIA PHARMACEUTICALS INCCOM0.99%$4M328.9K
37AEGLEA BIOTHERAPEUTICS INCCOM0.98%$4M609.7K
38EUCRATES BIOMEDICAL ACQU CORSHS · *W EXP 10/23/2020.95%$4M533.3K
39INSPINSPIRE MED SYS INCCOM0.93%$4M20.7K
40MREOMEREO BIOPHARMA GROUP PLCADS0.92%$4M1.25M
41VREXVAREX IMAGING CORPCOM0.88%$4M141.3K
42ILMNILLUMINA INCCOM0.88%$4M8.0K
43NTRANATERA INCCOM0.88%$4M33.2K
44OCULOCULAR THERAPEUTIX INCCOM0.84%$4M256.2K
45IMVTIMMUNOVANT INCCOM0.82%$4M335.0K
46IGM BIOSCIENCES INCCOM0.82%$4M42.5K
47HAEHAEMONETICS CORP MASSCOM0.82%$4M53.0K
48NANOSTRING TECHNOLOGIES INCCOM0.82%$4M54.5K
49DYNDYNE THERAPEUTICS INCCOM0.81%$4M166.6K
50CELCCELCUITY INCCOM0.81%$3M145.0K
51PROFPROFOUND MED CORPCOM NEW0.80%$3M210.3K
52TCR2 THERAPEUTICS INCCOM0.80%$3M209.1K
53GKOSGLAUKOS CORPCOM0.79%$3M40.4K
54KRMDREPRO MED SYS INCCOM0.78%$3M728.5K
55CRDFCARDIFF ONCOLOGY INCCOM0.77%$3M501.9K
56EYPTEYEPOINT PHARMACEUTICALS INCCOM NEW0.77%$3M370.6K
57TBPHTHERAVANCE BIOPHARMA INCCOM0.74%$3M220.0K
58ALPHA HEALTHCARE ACQUISTN COCL A · *W EXP 09/21/2020.74%$3M412.5K
59INTERSECT ENT INCCOM0.72%$3M182.5K
60CLDXCELLDEX THERAPEUTICS INC NEWCOM NEW0.72%$3M93.1K
61AVADEL PHARMACEUTICALS PLCSPONSORED ADR0.69%$3M440.6K
62STIMNEURONETICS INCCOM0.69%$3M184.6K
63XENEXENON PHARMACEUTICALS INCCOM0.67%$3M155.0K
64PHASEBIO PHARMACEUTICALS INCCOM0.67%$3M775.0K
65INFIQINFINITY PHARMACEUTICALS INCCOM0.65%$3M934.3K
66KALVISTA PHARMACEUTICALS INCCOM0.62%$3M111.8K
67TURMERIC ACQUISITION CORPCL A · *W EXP 10/08/2020.60%$3M338.7K
68HELIX ACQUISITION CORPCOM CL A0.60%$3M250.0K
69LIFESCI ACQUISITION II CORPCOM0.58%$3M250.0K
70SERES THERAPEUTICS INCCOM0.58%$2M104.6K
71TVTXTRAVERE THERAPEUTICS INCCOM0.58%$2M170.5K
72ADAMAS PHARMACEUTICALS INCCOM0.58%$2M470.9K
73RGNXREGENXBIO INCCOM0.56%$2M62.3K
74SURGALIGN HOLDINGS INCCOM0.56%$2M1.74M
75SARISSA CAPITAL ACQUISITN COUNIT 10/23/20270.54%$2M225.0K
76MORPHIC HLDG INCCOM0.54%$2M40.5K
77FULCFULCRUM THERAPEUTICS INCCOM0.52%$2M213.5K
78FAT BRANDS INC*W EXP 07/16/2020.52%$2M233.7K
79GRTXGALERA THERAPEUTICS INCCOM0.50%$2M219.9K
80CARA THERAPEUTICS INCCOM0.50%$2M150.0K
81RYTMRHYTHM PHARMACEUTICALS INCCOM0.48%$2M104.8K
82TARSTARSUS PHARMACEUTICALS INCCOM0.47%$2M70.6K
83LAKESHORE ACQUISITION I CORPUNIT 06/04/20260.47%$2M200.0K
84GIGINTERNATIONAL1 INCUNIT 05/19/20260.47%$2M200.0K
85FS DEVELOPMENT CORP IICOM CL A0.46%$2M200.0K
86JIYA ACQUISITION CORPCOM CL A0.46%$2M200.0K
87HEALTHCOR CATALIO ACQU CORPCL A SHS0.46%$2M200.0K
88SECOND SIGHT MED PRODS INCCOM NEW0.43%$2M373.9K
89IM CANNABIS CORPCOM NEW0.40%$2M321.8K
90EIGER BIOPHARMACEUTICALS INCCOM0.39%$2M197.5K
91CVRXCVRX INCCOM0.39%$2M60.0K
92CYTKCYTOKINETICS INCCOM NEW0.39%$2M84.3K
93KIROMIC BIOPHARMA INCCOM0.37%$2M333.5K
94PCTTWPURECYCLE TECHNOLOGIES INC*W EXP 01/28/2020.37%$2M130.9K
95PORTAGE BIOTECH INCCOM0.36%$2M75.0K
96ADICET BIO INCCOM0.34%$1M142.3K
97YUMANITY THERAPEUTICS INCCOM0.33%$1M123.7K
98VINCERX PHARMA INCCOM NEW0.32%$1M107.6K
99ELOXX PHARMACEUTICALS INCCOM0.31%$1M670.1K
100TAILWIND ACQUISITION CORPCOM CL A0.30%$1M128.4K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$42M19May 1, 202613F-HRchanges · EDGAR ↗
Q4 2025$25M18Feb 6, 202613F-HRchanges · EDGAR ↗
Q3 2025$628,2621Nov 4, 202513F-HRchanges · EDGAR ↗
Q2 2025$01Aug 7, 202513F-HRchanges · EDGAR ↗
Q1 2025$42M24May 13, 2025RESTATEMENTchanges · EDGAR ↗
Q4 2024$353M67Feb 13, 202513F-HRchanges · EDGAR ↗
Q3 2024$340M79Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$245M68Aug 15, 202413F-HRchanges · EDGAR ↗
Q1 2024$253M72May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$147M66Feb 14, 202413F-HRchanges · EDGAR ↗
Q3 2023$192M72Nov 14, 202313F-HRchanges · EDGAR ↗
Q2 2023$132M68Aug 14, 202313F-HRchanges · EDGAR ↗
Q1 2023$180M91May 15, 202313F-HRchanges · EDGAR ↗
Q4 2022$197M94Feb 14, 202313F-HRchanges · EDGAR ↗
Q3 2022$273M134Nov 14, 202213F-HRchanges · EDGAR ↗
Q2 2022$250M127Aug 15, 202213F-HRchanges · EDGAR ↗
Q1 2022$299M118May 16, 202213F-HRchanges · EDGAR ↗
Q4 2021$363M133Feb 14, 202213F-HRchanges · EDGAR ↗
Q3 2021$381M124Nov 17, 2021RESTATEMENTchanges · EDGAR ↗
Q2 2021$431M135Aug 13, 202113F-HRchanges · EDGAR ↗
Q1 2021$360M124May 6, 202113F-HRchanges · EDGAR ↗
Q4 2020$266M98Feb 16, 202113F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.